Immune-privileged Sertoli cells survive long term after allogeneic or xenogeneic transplantation without the use of immunosuppressive drugs, suggesting they could be used as a vehicle to deliver therapeutic proteins. As a model to test this, we engineered Sertoli cells to transiently produce basal levels of insulin and then examined their ability to lower blood glucose levels after transplantation into diabetic SCID mice. Mouse and porcine Sertoli cells transduced with a recombinant adenoviral vector containing furin-modified human proinsulin cDNA expressed insulin mRNA and secreted insulin protein. Transplantation of 5-20 million insulin-expressing porcine Sertoli cells into diabetic SCID mice significantly decreased blood glucose levels in a dose-dependent manner, with 20 million Sertoli cells decreasing blood glucose levels to 9.8 ± 2.7 mM. Similar results were obtained when 20 million insulin-positive, BALB/c mouse Sertoli cells were transplanted; blood glucose levels dropped to 6.3 ± 2.4 mM and remained significantly lower for 5 days. To our knowledge, this is the first study to demonstrate Sertoli cells can be engineered to produce and secrete a clinically relevant factor that has a therapeutic effect, thus supporting the concept of using immune-privileged Sertoli cells as a potential vehicle for gene therapy.
INTRODUCTION
time after allogeneic transplantation (7). This indicates genetically modified SC retain their immune-privileged abilities and therefore, could potentially be useful for Sertoli cells (SC) are somatic cells that reside within the seminiferous epithelium of the testis, where they gene therapy. However, these experiments were not designed to demonstrate whether SC could produce and play an important role in creating the immune-privileged environment of the testis (11, 13) . In addition to their secrete a therapeutic protein at a level relevant to treat a disease state. natural role in protecting the developing spermatozoa, SC are unique because they have the ability to survive One model to test the ability of SC to deliver a therapeutic product is transplantation of insulin-expressing long term without the use of immunosuppressive drugs when transplanted across immunologic barriers (20) SC into streptozotocin-induced diabetic mice. This model was chosen because blood glucose levels allow such as in allogeneic (2,18) or xenogeneic (9,12,23) transplantation. For example, porcine SC have been for an easy measure of biologically functional insulin. Engineering a cell to produce insulin is not straightforfound to survive transplantation as discordant xenografts in dogs and rodents (9,12).
ward, because the ideal cell must be glucose responsive, process proinsulin correctly, and secrete functional insuThe ability of SC to survive transplantation when most other cells are destroyed led to the hypothesis that lin. Because our current objective was to determine whether SC can be engineered to produce a factor, in SC can be engineered as a vehicle for gene therapy. Previously, we tested this hypothesis by transplanting green this case insulin, at a level to treat a disease, the more complex issue of glucose regulation was not addressed fluorescent protein (GFP)-positive SC, isolated from transgenic mice engineered to constitutively produce by the current study. However, the ability of SC to produce functional insulin is important and our goal was to GFP, as allografts into BALB/c mice (7). Examination of the grafts 60 days posttransplantation demonstrated accomplish this with the addition of furin cleavage sites to proinsulin cDNA. In islet β-cells, proinsulin is that GFP-positive SC survived for a prolonged period of cleaved by the prohormone convertases (PC) 2 and 3 to with the ILAR Care and Use of Laboratory Animals and Texas Tech University Institutional Animal Care and generate mature insulin and C-peptide (3) . Given that PC2 and 3 are not ubiquitously expressed, to allow Use Committee approved protocols and the guidelines of the NIH. proper cleavage and secretion of mature insulin in cells that lack these enzymes, PC2 and 3 cleavage sites are
Cell Isolation and Adenoviral Transduction converted to furin cleavage sites. Furin is a ubiquitously expressed member of the convertase family that pro-SC were isolated from neonatal pigs or pubertal mice by collagenase and trypsin digestion as described precesses proteins in the constitutive secretory pathway (28) . The addition of furin cleavage sites to proinsulin viously (8,9). A typical NPSC preparation after 2 days of culture consists of 92% SC and 2% myoid cells (9) cDNA allows cells that contain the constitutive pathway of secretion to properly process proinsulin and leads to and a typical preparation of mSC at the time of isolation contains 74% SC, 6% myoid cells, and 20% germ cells secretion of the mature product, functional insulin. Furin-modified proinsulin cDNA constructs have been (25) . The germ cells in the mSC preparation are not expected to contribute significantly as they do not survive used previously to create insulin-secreting hepatocytes, acinar cells, kidney cells, and muscle cells (14,19,24, when cultured at 37°C (17) . Cells were cultured overnight as a monolayer on tissue culture treated plates with 29). To the best of our knowledge, the ability of SC to produce insulin has not been examined.
Dulbecco's modified Eagle medium (DMEM) plus 10% fetal bovine serum (FBS) at 37°C. The next day these The objective of the current study was to determine whether SC could be altered to express a therapeutic cells were transduced with a recombinant adenoviral vector containing furin-modified human proinsulin protein at a level that could treat a disease. The model we used was basal insulin production as a method to cDNA (AdCMVhInsM) under the control of the cytomegalovirus (CMV) promoter (24) . SC were transduced lower blood glucose levels in streptozotocin-induced diabetic mice. In view of the fact that our future objective at a multiplicity of infection (MOI) of 50, 75, 100, or 200 and cultured for 2-20 days in DMEM plus 2% FBS. is to create transgenic animals with SC that produce therapeutic factors, we tested our current hypothesis Controls included cells that were nontransduced (MOI 0) and cells that were transduced with a recombinant with both mouse (a model for transgenic mice) and porcine (a model for a clinically relevant source of tissue) adenoviral vector containing wild-type human proinsulin cDNA (AdCMVhInsWT; i.e., without the furin modifi-SC. Neonatal porcine Sertoli cells (NPSC) and pubertal mouse Sertoli cells (mSC) were transduced with a recation) under the control of the CMV promoter (24) or an irrelevant recombinant adenoviral vector containing combinant adenoviral vector engineered to express furin-modified human proinsulin cDNA (24) . These green fluorescent protein (GFP) cDNA (AdRSVGFP) under the control of the Rous sarcoma virus (RSV) protransduced SC were characterized for insulin production and transplanted into streptozotocin-induced diabetic moter at a MOI of 100. SCID mice. Blood glucose levels were measured as a RNA Isolation and RT-PCR therapeutic endpoint and achievement of normoglycemia was considered a success.
Freshly isolated SC were cultured overnight as a monolayer on six-well plates with DMEM plus 10% MATERIALS AND METHODS FBS. AdRSVGFP and further cultured in DMEM plus 2% obtained were of the expected size (180 bp for insulin FBS. Medium was changed every 2 days and supernaand 500 bp for β-actin). Additionally, the furin-modified tant was collected to measure insulin secretion 2, 6, 12, insulin PCR product was extracted from the agarose gel 16, and 20 days posttransduction for the AdCMVhInsM using the QiaexII kit (Qiagen, Valencia, CA), ligated or at day 2 posttransduction for the AdCMVhInsWT or into the pCRII-TOPO vector (Invitrogen), and sequenced.
AdRSVGFP and stored at −80°C. The amount of human Unknown sequences were analyzed using BLAST insulin secreted by the SC was quantified using a human (NCBI) and compared with known GenBank sequences.
insulin ELISA kit (Linco Research, Inc., St. Charles, The sequenced PCR product was identical to human in-MO) as described by the manufacturer. This kit detects sulin except for the furin modifications. Primers used human insulin at 100% specificity, des(64,65) human were: human insulin forward 5′-GGG ACC TGA CCC proinsulin at 117% specificity and des(31,32) human AGC CGC A and reverse 5′-CAG GCT GCC TGC proinsulin at 0.3% specificity. Human proinsulin and hu-ACC AGG G, and β-actin forward 5′-TGT ATT CCC man C-peptide are not detectable at concentrations up to CTC CAT CGT G and reverse 5′-GGA TCT TCA TGA 120 nM with this kit. The amount of human proinsulin GGT AGT CTG TC.
secreted by the SC was quantified using a human proinsulin ELISA kit (Linco Research, Inc.) as described by Immunohistochemistry the manufacturer. This kit detects intact human proinsu-SC (2.5 × 10 5 cells/well) were cultured overnight on lin at 100% specificity and des(64,65) human proinsulin chamber slides in DMEM plus 10% FBS (n > 3). The at 36% specificity. Human insulin and des(31,32) human next morning, cells were transduced with 0-200 MOI proinsulin are not detectable with this kit. DMEM plus of AdCMVhInsM or 100 MOI of AdCMVhInsWT or 2% FBS was used as the control. AdRSVGFP and further cultured in DMEM plus 2%
Transplantation and Graft Characterization FBS. Slides were collected after 2-20 days for the AdC MVhInsM or at day 2 posttransduction for the AdCMV For transplantation, cells that had been transduced with AdCMVhInsM or AdRSVGFP at a MOI of 100 hInsWT or AdRSVGFP and fixed with 1% paraformaldehyde for 30 min, permeabilized with 0.1% Triton Xand cultured for 24 h were transferred to nontreated petri dishes and cultured in Ham's F10 media (supplemented 100, and immunostained for insulin or C-peptide. The C-peptide antibody recognizes both C-peptide and the with 10 mM D-glucose, 2 mM L-glutamine, 50 µM isobutylmethylxanthine, 0.5% bovine serum albumin, 10 proinsulin molecule (15). Slides were incubated with 10% hydrogen peroxide, blocked with 20% normal goat mM nicotinamide, 100 U/ml penicillin, 100 µg/ml streptomycin) and 10% FBS for 24 h at 37°C to allow the serum, and incubated with guinea pig polyclonal antiswine insulin (1:1000; DAKO, Carpinteria, CA) or formation of SC aggregates (50-300 µm diameter) (6,7,9) prior to transplantation under the kidney capsule. mouse anti-human C-peptide (1:500; Cedarlane, Burlington, NC) primary antibodies for 30 min. This was
The number of SC was calculated as described (9) based on 6.6 pg of DNA/cell and using a PicoGreen dsDNA followed by incubation with the appropriate biotinylated secondary antibody (1:200; Vector Laboratories, Burlquantitation assay (Invitrogen). Aliquots consisting of 5, 10, or 20 × 10 6 cells were placed in polypropylene miingame, CA). Sections were then incubated with the ABC-enzyme complex (Vector Laboratories) followed crocentrifuge tubes, aspirated into polyethylene tubing (PE-50), pelleted by centrifugation, and gently placed by diaminobenzadine (DAB; Biogenex, San Ramon, CA) as chromagen and counterstained with hematoxylin.
within the left renal subcapsular space of isofluoraneanesthetized diabetic SCID mice (5). Negative controls included cells from each treatment group that were put through the same procedure without Grafts were removed for histological analysis between 1 and 30 days posttransplantation. The graft-bearprimary antibody. All negative controls lacked a positive reaction. The percentage insulin-positive cells at day 17 ing kidneys were immersed in Z-fix (Anatech LTD, Battle Creek, MI) and embedded in paraffin. Tissue sections were determined after immunostaining for insulin. For each slide a minimum of 400 cells were counted. Images were immunostained for insulin, vimentin (to identify NPSC), GATA-4 (to identify mSC), or proliferating cell were acquired with a Zeiss Axiostar plus microscope and AxioCam MRc digital camera. Images were comnuclear antigen (PCNA) as described previously (8,9 1C, d and B, lane 3). The amount of insulin se-CA), and guinea pig polyclonal anti-swine insulin (1: 1000; DAKO). After incubation with primary antibody, creted into the culture media, as measure by insulin ELISA, was also below the limit of detection in these sections were incubated with biotinylated secondary antibodies followed by the ABC-enzyme complex with cells (Table 1) . Cells transduced with AdCMVhInsWT expressed insulin mRNA (Fig. 1B, lane 4) but ineffi-DAB as chromagen. All sections were counterstained with hematoxylin. Negative controls included tissue secciently processed proinsulin and thus demonstrated very low insulin protein expression (Fig. 1C, b) . In contrast, tions that were put through the same procedure without primary antibody. All negative controls lacked a positive NPSC transduced with the AdCMVhInsM produced insulin mRNA (Fig. 1B , lane 5) and protein (Fig. 1A, d ) reaction.
and secreted 18-fold higher levels of insulin than NPSC Statistical Analysis transduced with AdCMVhInsWT (Table 1) . Data are expressed as the mean ± SEM of n indepenIn addition, the amount of proinsulin secreted into the dent experiments. The significance of differences beculture media was measured by proinsulin ELISA and tween two groups was calculated by paired or unpaired was not detected in cells nontransduced or transduced Student t-test. For multiple comparisons, a one-way with AdRSVGFP or AdCMVhInsM ( Table 1) . This inanalysis of variance (ANOVA) was used. When signifidicates the addition of furin cleavage sites to proinsulin cance was observed, comparisons between groups were allowed NPSC to efficiently process and secrete insulin. made using the Fisher's PLSD test. A value of p < 0.05
Proinsulin was present in the culture media of cells was considered significant. transduced with AdCMVhInsWT (Table 1) , indicating the PC2 and PC3 cleavage sites in wild-type human pro-RESULTS insulin were inefficiently processed. Additional confirInsulin Production by Adenovirus-Transduced Porcine mation that NPSC transduced with AdCMVhInsM synSertoli Cells thesize insulin protein was obtained by visualization of a positive immunohistochemical reaction for human speIn order to determine the optimal MOI for insulin protein production, NPSC were transduced with a recific C-peptide (Fig. 1C, a) . Nontransduced NPSC (data not shown) and NPSC transduced with AdRSVGFP combinant adenoviral vector engineered to express furin-modified human proinsulin cDNA (AdCMV (Fig. 1C, e) were negative for C-peptide. NPSC transduced with AdCMVhInsWT were positive when immuhInsM) at a MOI of 0, 50, 75, 100, or 200; 2 days posttransduction insulin immunohistochemistry and ELISA nostained with the C-peptide antibody (Fig. 1C, c) , which is expected because C-peptide is also present in were performed on the cultured cells and supernatent, respectively. By immunohistochemistry there was an approinsulin. parent dose-dependent increase in the amount of insulin Transplantation of Insulin-Expressing Porcine detected within the NPSC (Fig. 1A, a-e) with the highSertoli Cells est amount at 200 MOI. However, at 200 MOI the cells appeared unhealthy (Fig. 1A, e) , while at 100 MOI the NPSC transduced with AdCMVhInsM at the optimal MOI of 100 were cultured for 2 days and then transcells were both healthy and produced insulin (Fig. 1A,  d) . Additionally, the amount of insulin secreted by the planted underneath the kidney capsule of diabetic SCID mice. SCID mice were used as recipients in order to test NPSC into the culture media as measured by ELISA was higher at 100 MOI (Table 1) than at 200 MOI (7.3 the concept of engineering SC without interference from the immune system. Transplanted insulin-expressing ± 3.6 × 10 −7 µg of insulin/cell). Therefore, the amount of AdCMVhInsM needed for optimal insulin protein pro-NPSC significantly decreased blood glucose levels within 1 day after transplantation in a dose-dependent duction by NPSC was 100 MOI and all further experiments were performed at a MOI of 100. manner with 5, 10, and 20 million NPSC leading to an average decrease of 8.0, 10.3, and 16.2 mM glucose, The production of insulin mRNA and protein by NPSC transduced with AdCMVhInsM at a MOI of 100 respectively (Fig. 2) . When 20 million NPSC were transplanted, the average blood glucose levels dropped was analyzed by RT-PCR (Fig. 1B) , immunohistochemistry (Fig. 1A, C) , and ELISA. Controls included NPSC to 9.8 ± 2.7 mM and remained significantly decreased for 5 days. In contrast, transplantation of 20 million nontransduced, transduced with a recombinant adenoviral vector containing wild-type human proinsulin cDNA NPSC transduced with AdRSVGFP at a MOI of 100 had (Fig. 1A, d , and Fig. 3A and B) , and then the number of insulin-positive NPSC decreased ( Fig. 3C) the slides for up to 20 days (data not shown).
Characterization and Transplantation of Insulin-Expressing
Mouse Sertoli Cells no effect on blood glucose levels ( Fig. 2A , n = 5; four of five mice had no change in blood glucose levels and
The ability of NPSC to produce biologically relevant levels of insulin was examined because porcine cells the fifth mouse was found dead after transplantation due to hyperglycemia).
have potential as a relevant source of tissue for clinical xenotransplantation. However, because our ultimate goal The adenoviral vector is ideal for efficient high expression of the gene of interest. However, the epichrois to create a transgenic animal with modified SC that can be used as an unlimited source of SC for clinical mosomal nature of the adenoviral vector does not allow for stable integration of the insulin construct into the SC xenotransplantation, the first step will be to create transgenic mice with genetically modified SC. Therefore, it genome. Additionally, the NPSC were proliferating, as demonstrated by a positive signal when immunostained was important to examine the ability of mSC to produce biologically relevant levels of insulin. SC isolated from for PCNA (data not shown). Together, these factors probably led to a loss of insulin expression, which was 10-12-day-old mice were transduced with AdCMV hInsM at a MOI of 100 and results comparable to those the reason for the transient decrease in blood glucose levels and subsequent return to the diabetic state (>20 reported for NPSC were obtained. mSC engineered to express furin-modified human proinsulin expressed inmM) within 15 days ( Fig. 2A) . To confirm the loss of insulin expression, nephrectomies were performed besulin mRNA (Fig. 4A, lane 5) , produced insulin protein (Fig. 4B, a) , and secreted insulin into the culture media tween 3 and 30 days after transplantation and tissue sections were immunostained for detection of NPSC (vi-( Table 2 ). In contrast, nontransduced mSC and mSC transduced with AdRSVGFP were negative for insulin mentin) and insulin (Fig. 2B) . Consistent with a significant decrease in blood glucose levels prior to 5 mRNA (Fig. 4A , lanes 2 and 3) and protein (Fig. 4B, c and data not shown) and insulin was not detectable in days posttransplant, at 3 days the majority of the cells present within the NPSC grafts were insulin positive the culture media (Table 2) . mSC transduced with AdC MVhInsWT expressed insulin mRNA (Fig. 4A , lane 4) (Fig. 2B, a and b) . As the blood glucose levels rose, the number of insulin-positive NPSC also appeared to but very little protein was detected by imunohistochemistry (Fig. 4B, b ) and significantly less insulin was decrease (Fig. 2B , column 2) with fewer insulin-positive NPSC present at 8 and 13 days (Fig. 2B, c-f) , and only secreted from these cells (Table 2 ) than cells transduced with AdCMVhInsM. Proinsulin was not detected in the 2 to 10 insulin-positive cells detected within the tissue sections after 30 days (Fig. 2B, h ). The loss of insulin culture media of mSC nontransduced, transduced with AdRSVGFP, or transduced with AdCMVhInsM, while expression was most likely due to loss of the adenoviral vector and not NPSC death as the majority of the cells cells transduced with AdCMVhInsWT secreted proinsulin (Table 2 ). C-peptide was detected in mSC transduced within the grafts were vimentin-positive from 3 to 30 days (Fig. 2B, column 1) . As expected, immune cell inwith AdCMVhInsM (Fig. 4B, d ), while nontransduced mSC (data not shown) and mSC transduced with AdRS filtrate was not detected in the grafts (Fig. 2B) .
VGFP (Fig. 4B, f) were negative. As expected, mSC In Vitro Culture of Insulin-Positive Porcine transduced with AdCMVhInsWT were positive for proSertoli Cells insulin (Fig. 4B, e) . Moreover, when 20 million insulin-expressing mSC NPSC transduced with AdCMVhInsM at a MOI of 100 were cultured for 2 to 20 days posttransduction, mewere transplanted under the kidney capsule of diabetic SCID mice, blood glucose levels dropped significantly dia was collected for human insulin ELISA, and cells within 1 day, were as low as 6.3 ± 2.4 mM within 2 days and remained significantly decreased for 4 days (Fig. 5A) . Transplantation of mSC transduced with the AdRSVGFP had no effect on blood glucose levels (Fig.  5A , n = 1; two mice were initially transplanted but the second mouse died due to the diabetic state). Immunohistochemical analysis of AdCMVhInsM transduced mSC grafts harvested between 8 and 30 days posttransplantation confirmed the proliferation (by PCNA immunohistochemistry; data not shown) and survival of GATA-4-positive mSC and no immune cell infiltrate throughout the study (Fig. 5B, a and c) . Similar to the results with NPSC, there was an apparent decrease in the number of insulin-positive mSC over time. At 8 days, several insulin-positive mSC were detected within the grafts (Fig. 5B, b) ; the number of insulin-positive cells then appeared to decrease with far fewer insulinpositive mSC detectable after 30 days (Fig. 5B, d ). Similarly, when mSC transduced with AdCMVhInsM were cultured in vitro for 5 to 20 days, the number of insulinpositive cells decreased dramatically between 5 and 12 days (Fig. 5B, f and g ) with very few insulin-positive cells remaining at 20 days (Fig. 5B, h) . Thus, insulinpositive NPSC and mSC are able to synthesize and secrete functional insulin protein at biologically relevant levels that lowered blood glucose levels in diabetic mice. This demonstrates the potential of genetically engineered SC to act as a vehicle for gene therapy.
DISCUSSION
Allogeneic transplantation as a replacement therapy for damaged or destroyed cells has potential in treatment of diseases such as type I diabetes or Parkinson's disease. Still, this procedure is limited by the need for chronic immunosuppressive therapy and the paucity of organ donors (16). To overcome the shortage of available organ donors, one could potentially use pigs as an unlimited supply of transplantable tissue. Even so, the benefits of transplantation of porcine tissue, such as pancreatic islets, remain threatened by immunological destruction (10). Engineering an immune-privileged cell, like the SC, that would survive transplantation without the need for immunosuppression to produce therapeutically relevant factor(s) is a novel approach to bypass these issues. days) (7). However, while this verified the immune-privileged status of genetically modified SC, it did not demonstrate their ability to either express a clinically relevant factor or to treat a disease. More recently, Triveldi tively. This value seems excessive when compared to the amount of insulin typically used for treatment of humans with diabetes (0.5-1.0 U/kg). However, it is important to point out that human insulin has been shown et al. demonstrated short-term production of human neurotrophin-3 (hNT-3) by SC after allogeneic transplantato be less effective in rodents than in humans, where 20-40 U/kg was needed to normalize blood glucose levtion (30) . In that article, Lewis rat SC were transduced with an adenoviral vector that expressed hNT-3 under els in rats (21,31). Taking this into consideration the amount of insulin secreted by the transduced mSC or the control of the CMV promoter and transplanted as allografts to the injured spinal cord of Sprague-Dawley NPSC and needed to lower blood glucose levels was similar to the previous reports. rats. Cell survival and hNT-3 production were examined. Allogeneic SC survived for at least 42 days, but
The goal of gene therapy is to restore wild-type function in disease states by replacing defective or deficient hNT-3 production by these cells was only detectable for 3 days after transplantation. While these results support proteins. While viral vectors are the most commonly used gene therapy method, because they generate suffithe concept of genetically modified SC surviving transplantation and expressing a transgene, they were unable cient expression of the gene of interest (26, 27) , the use of these vectors raises additional concerns regarding stato demonstrate in vivo function of the transgene.
In the current study, we explored the possibility of ble gene expression, safety, toxicity, and immunogenicity (22, 27) . As an alternative, generation of transgenic engineering SC to produce a therapeutically relevant protein; specifically, we modified them to express basal animals that express therapeutic factors could overcome the issues of transient gene expression and safety, but levels (nonglucose regulated) of insulin. SC isolated from neonatal pigs and pubertal mice were transduced would still be subject to immune rejection. The use of SC, isolated from transgenic animals, engineered to exwith AdCMVhInsM and examined for the ability to express and secrete biologically active insulin. As shown press clinically relevant factors specifically in SC (using a SC specific promoter) presents a novel method by in our results, these SC produced insulin mRNA and protein and secreted functional insulin. In addition, insuwhich gene therapy can overcome several of these issues, by providing long-term gene expression and an imlin was secreted at levels able to normalize blood glucose levels after transplantation into immune-compromune-privileged environment. Combining the results of the current study with our previous experiments using mised diabetic SCID mice. To the best of our knowledge, this is the first study to show genetically modified SC GFP transgenic mice (7), our findings provide further support for this concept. can express levels of a factor that can treat a disease in vivo.
In theory, genetically modified SC could be designed to produce many different therapeutically relevant facEven so, in this study, the expression of insulin was transient. Because our current objective was to test the tors, such as insulin, glucagon-like peptide-1 (GLP-1), or factor VIII for the treatment of diabetes or hemoconcept that SC can be genetically engineered as a vehicle for gene therapy, an adenoviral vector was used to philia, respectively. The current study examined the production of insulin by SC after introduction of furin-moddrive insulin production. Use of an adenoviral vector as a delivery system was advantageous because of ease of ified human proinsulin cDNA. The addition of furin cleavage sites allowed SC to properly process and seuse and the possibility of high levels of gene expression in the majority of transduced cells (26, 27) . However, crete functional insulin. While our goal was not to make this construct glucose responsive, but instead to provide due to the epichromosomal location of the vector, combined with proliferation of the SC, we were only able proof of concept, this construct still has potential therapeutic value by providing continuous basal levels of into achieve transient gene expression (26, 27) . There are gated, but to date, no solution has been found (1, 32, 33 
